By Jonathan Gardner | Published June 22, 2026
In a significant pivot that signals a cooling of the contentious regulatory environment characterizing the previous administration, the Food and Drug Administration (FDA) has cleared a path forward for Regenxbio’s experimental gene therapy, Navsunli. The move marks a definitive step by current agency leadership to resolve a mounting backlog of rejections issued during the tenure of former commissioner Marty Makary and his biologics review chief, Vinay Prasad—decisions that had been widely criticized by the biopharmaceutical industry for contradicting established regulatory agreements.
Regenxbio announced on Monday that it has reached alignment with the FDA regarding the necessary steps to pursue an accelerated approval for Navsunli, a gene therapy intended to treat Hunter syndrome, a rare and devastating neurodegenerative condition. Crucially, the agency has retracted its previous demand that the company initiate new clinical trials—specifically those incorporating placebo-controlled arms—acknowledging that the existing clinical data package is sufficient to support a formal review.
A Chronology of Regulatory Friction
The path to this week’s breakthrough was anything but smooth. The relationship between Regenxbio and the FDA had hit an impasse in February 2026, when the agency issued a formal rejection of the company’s biologics license application (BLA) for Navsunli.
At the time, the FDA’s decision was underpinned by a stringent interpretation of trial design, specifically targeting the company’s reliance on "natural history" data. This methodology, which compares the disease progression of current trial participants against historical data from patients who lived with the disease before the experimental therapy was available, is a standard—and often necessary—tool in the rare disease space, where patient populations are too small to support massive, randomized controlled trials.
However, under the leadership of Marty Makary and Vinay Prasad, the FDA became notably hostile toward such flexibility. Prasad, in particular, was an outspoken critic of surrogate endpoints and non-randomized trial designs, frequently arguing that only placebo-controlled, "gold standard" trials could provide the rigor required for regulatory approval. This ideological shift led to a series of high-profile clashes where the FDA appeared to walk back previous "agreements" made with developers regarding the data requirements for approval.
Following the February rejection, Regenxbio initiated a formal appeal process. The company entered into high-level discussions with agency staff, who eventually guided the developer toward a "Type A" meeting—the FDA’s most urgent channel for resolving regulatory disputes. This meeting provided the forum to review the existing long-term biomarker data, leading to the current consensus that no additional trials are required.
The Science of Rare Disease: Navsunli and the "Surrogate" Debate
To understand the stakes of this reversal, one must look at the unique challenges of Hunter syndrome. A rare, X-linked genetic disorder caused by a deficiency in the enzyme iduronate-2-sulfatase, the disease causes progressive physical and neurological decline. For companies like Regenxbio, developing a therapy requires navigating a landscape where conducting a "traditional" trial—with a placebo group—is often deemed unethical or physically impossible due to the limited pool of eligible patients.
The FDA’s earlier rejection of Navsunli centered on the use of surrogate endpoints. In clinical research, a surrogate endpoint is a measure—such as a specific biomarker or protein level—that is used as a substitute for a direct measure of how a patient feels, functions, or survives. While regulators typically prefer "hard" clinical outcomes, they have historically granted leeway in rare diseases, recognizing that waiting for a patient to decline significantly before proving a drug’s efficacy is not in the interest of public health.
The Makary-Prasad era’s refusal to accept these precedents created a bottleneck that threatened to stifle innovation in the gene therapy sector. By rejecting applications based on methodologies they had previously permitted, the agency created a climate of deep uncertainty for biotech investors and researchers alike.
A Broader Pattern of Regulatory Correction
Regenxbio’s success is not an isolated incident; it is part of a growing trend of "reprieves" being granted to companies that had their applications stalled during the 2025–2026 period.
The agency’s current leadership, tasked with restoring stability, has been quietly reviewing these Makary-era decisions. Other notable biotech entities, including the gene therapy developer UniQure, cancer-focused Replimmune, and pharmaceutical giant Sanofi, have all reported similar constructive engagements with the FDA in recent months. Each of these companies had faced similar roadblocks: sudden demands for additional trials or a rejection of established scientific methodologies that had been agreed upon during earlier development phases.
Industry analysts view this as a clear signal that the FDA is returning to its traditional role as a partner in the drug development process, rather than an adversarial force. Sean McCutcheon, an analyst at Raymond James, noted in a report to clients that while "wrinkles" remain, the shift represents a "significantly more flexible" approach that portends a much more favorable environment for rare disease drug development.
Official Responses and Market Reaction
The market reaction to the news was swift and positive. Shares of Regenxbio surged by as much as 17% in Monday’s pre-market trading, reflecting investor relief that the "overhang" of the FDA rejection had been removed.
In a public statement, Regenxbio CEO Curran Simpson emphasized the importance of the agency’s pivot, noting that the company is "encouraged by recent signals from the new FDA leadership reinforcing a commitment to address the unique nature of rare diseases." Simpson added that the company remains dedicated to utilizing the accelerated approval pathway to bring transformative therapies to patients who currently have no other treatment options.
The FDA, while typically reticent to discuss specific company interactions, has signaled a broader administrative push to streamline the review of products that have received "breakthrough therapy" or "orphan drug" designations. The agency’s willingness to move to an "expedited" review timeline for the resubmitted Navsunli application is a testament to this shift.
Implications for the Future of Drug Development
The reversal of the Navsunli rejection carries profound implications for the pharmaceutical industry.
1. Re-establishing Predictability: The most immediate impact is the restoration of the "regulatory contract." When the FDA reneges on agreements, it shatters investor confidence and complicates long-term financial planning for biotech firms. By returning to a predictable, evidence-based review process, the agency is stabilizing the biotech sector.
2. The Future of Rare Disease Trials: The decision serves as a de facto affirmation that "natural history" data and surrogate endpoints remain valid, legitimate components of the drug development toolkit. This protects the viability of future research into ultra-rare diseases where large-scale clinical trials are not feasible.
3. Personnel and Policy: The retreat from the Makary-Prasad policy framework suggests that while the FDA remains rigorous, it is rejecting the notion that scientific "purity" should override the urgent needs of patient populations. The agency is moving back toward a risk-benefit assessment that accounts for the severity of the disease in question.
Conclusion: A Turning Point?
As the FDA prepares to review the resubmitted application for Navsunli in the coming months, the case will likely be viewed as a milestone in the post-Makary era. The "correction" currently underway is more than just a win for Regenxbio; it is a recalibration of the FDA’s mission.
For patients suffering from Hunter syndrome and other rare diseases, the delay caused by the previous regulatory cycle was more than a financial inconvenience—it was a period of profound uncertainty regarding access to life-saving technology. With the FDA now aligned on a path toward accelerated approval, the industry will be watching closely to see if this flexibility translates into a more robust pipeline of approvals for the remainder of the year.
The message from the FDA seems clear: innovation is once again being encouraged, and the agency is prepared to engage with the unique realities of 21st-century medicine, rather than relying on the rigid, one-size-fits-all requirements that characterized the recent past. As Regenxbio moves toward its July meeting and subsequent resubmission, the broader biotech community breathes a collective sigh of relief, hopeful that the era of unpredictable rejections is finally coming to a close.
